Full-Time

Principal

Posted on 6/27/2024

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals for genetic disorders

Compensation Overview

$130k - $220k/yr

+ Bonus + Equity + Company-sponsored benefit programs

Senior, Expert

New York, NY, USA

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
Data Science
Requirements
  • Outstanding educational background
  • Desire to operate in a highly entrepreneurial environment with substantial opportunity and uncertainty
  • Ability to wear multiple hats in a fast-paced or early-stage environment
  • Comfort with responsibility in a high-velocity, high-accountability environment
  • Specialized knowledge set in one or more of the following areas: Healthcare technology, Medicine and/or life sciences, Data science, advanced statistical techniques (ML, etc.), or broader technology, Finance and corporate transactions
  • Experience in building, as a principal or participant, new ventures or organizations, preferably with a desire to do so in the field of healthcare or related technology, or experience in investing in the same
Responsibilities
  • Participating in early-stage ideation by mapping ideas to a variety of qualifying factors, including time to market, sources of Roivant advantage, validation path, market size, etc.
  • Leading structured evaluation of ideas, developing and executing workplans that de-risk ideation ideas by appropriately ordered and costed evaluation of markets, competitors, product space, and other key factors
  • Driving the initial stages of company building, including early business development, alpha development, and verification of demand
  • Recruiting the CEO and other key leaders of the incubated company
  • Overseeing the success of the incubated opportunities post-CEO through board positions / oversight

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a diverse pipeline of drug candidates. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's acquisition of Dermavant expands its dermatology portfolio, enhancing market presence.
  • Collaboration with Bayer to create Pulmovant strengthens Roivant's position in pulmonary hypertension.
  • Roivant's innovative portfolio and strategic partnerships make it a strong buy opportunity.

What critics are saying

  • Integration challenges may arise from Roivant's acquisition of Dermavant.
  • Failure of lupus treatment brepocitinib could impact investor confidence.
  • Reliance on partnerships, like with Roche, poses risks if outcomes are not met.

What makes Roivant Sciences unique

  • Roivant builds nimble biotech companies called Vants to streamline drug development.
  • Genevant, a Roivant subsidiary, specializes in RNA therapeutics using proprietary delivery platforms.
  • Roivant's unique business model combines in-house development with strategic partnerships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Investing.com
Feb 24th, 2025
Roivant Sciences president Eric Venker sells $1.07 million in shares

Jennifer Humes has been appointed to succeed Kumar as the new Principal Accounting Officer for Roivant Sciences Ltd. and Chief Accounting Officer for Roivant Sciences, Inc.

Finsmes
Feb 3rd, 2025
Zest Health Raises $13M in Funding

Zest Health, a NYC-based virtual care company focused on treating patients with inflammatory skin diseases, raised $13M in Seed funding

Stock Target Advisor
Jan 15th, 2025
Roivant Sciences Ltd. AI-Stock Analysis: A Strong Buy Opportunity

Stock Target Advisor-AI has highlighted Roivant as a "Top Pick", citing its solid track record in drug development, strategic partnerships, and an innovative portfolio of treatments aimed at addressing significant medical needs.

TipRanks
Oct 28th, 2024
Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio

Roivant Sciences acquires Dermavant, expanding dermatology portfolio.

The Pharma Letter
Sep 13th, 2024
The week in pharma: action, reaction and insight - week to September 13, 2024

Roivant Sciences announced a collaboration with Germany's Bayer, creating a new 'vant' - called Pulmovant - to in license moslicigual for pulmonary hypertension.

INACTIVE